- Home
- EXPI vs NAMS Comparison
EXPI vs NAMS Comparison
Compare EXPI & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EXPI | NAMS |
|---|---|---|
| Founded | 2008 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 4.1B |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | EXPI | NAMS |
|---|---|---|
| Price | $6.76 | $33.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $9.75 | ★ $46.75 |
| AVG Volume (30 Days) | 1.0M | ★ 1.4M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $500,147,681.00 | N/A |
| Revenue This Year | $6.26 | $17.96 |
| Revenue Next Year | $5.50 | $540.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 220.39 | N/A |
| 52 Week Low | $5.66 | $17.76 |
| 52 Week High | $12.23 | $42.21 |
Technical Indicators
Market Signals| Indicator | EXPI | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 60.03 | 46.71 |
| Support Level | $5.68 | $29.26 |
| Resistance Level | $6.87 | $37.25 |
| Average True Range (ATR) | 0.23 | 1.98 |
| MACD | 0.04 | -0.19 |
| Stochastic Oscillator | 81.56 | 5.52 |
Price Performance
Historical ComparisonAbout EXPI eXp World Holdings Inc.
eXp World Holdings Inc is a cloud-based residential real estate company. The company owns and operates a cloud-based real estate brokerage and a technology platform business that develops and uses immersive technologies that help businesses increase their effectiveness and reduce costs from operating in traditional brick-and-mortar office spaces. Its business categories include Real Estate Brokerage, Technology Products and Services, Title, Escrow, Settlement Services, and Mortgage Brokerage Services.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.